Related Experiment Videos
Clinical studies on alpha 2 plasmin inhibitor
S Roman1, O Knauer, M Cucuianu
1Medical Clinic No. 1, Cluj-Napoca, Romania.
Medecine Interne
|January 1, 1990
Summary
Plasma levels of alpha 2 plasmin inhibitor (alpha 2 PI) were decreased in liver cirrhosis patients and increased in nephrotic and hypertriglyceridemic patients. Alpha 2 PI levels impact blood clot lysis rates, affecting fibrinolysis.
Area of Science:
- Biochemistry
- Hematology
- Clinical Chemistry
Background:
- Alpha 2 plasmin inhibitor (alpha 2 PI) is a key regulator of fibrinolysis.
- Understanding alpha 2 PI's role in various diseases is crucial for assessing hemostasis.
- Dysregulation of fibrinolysis is implicated in several pathological conditions.
Purpose of the Study:
- To investigate plasma levels of alpha 2 PI in patients with decompensated cirrhosis, nephrotic syndrome, and hypertriglyceridemia.
- To correlate alpha 2 PI levels with functional clot lysis assays.
- To elucidate the impact of alpha 2 PI on fibrinolysis in different clinical settings.
Main Methods:
- Measurement of plasma alpha 2 PI levels using immunological and functional assays.
- Comparison of alpha 2 PI levels between patient groups and healthy controls.
- Assessment of dilute blood clot lysis time in patient cohorts.
Main Results:
- A strong correlation (r = 0.793) was observed between immunological and functional alpha 2 PI assays.
- Significantly decreased alpha 2 PI levels were found in decompensated cirrhosis patients.
- Slightly increased alpha 2 PI levels were noted in nephrotic and hypertriglyceridemic patients.
- Accelerated clot lysis was observed in nephrotic patients, while lysis was delayed in hypertriglyceridemic patients, despite similar alpha 2 PI levels.
Conclusions:
- Plasma alpha 2 PI levels vary significantly across different disease states.
- The rate of clot lysis is influenced by factors beyond just alpha 2 PI concentration, including the balance of plasminogen activators and inhibitors.
- Severe alpha 2 PI deficiency can accelerate clot lysis, whereas increased levels, coupled with impaired plasminogen activation, can impede fibrinolysis.